Cargando…

Prevalence of potential drug-drug interactions in Swedish pediatric outpatients

PURPOSE: To describe the occurrence of potential drug-drug interactions (DDIs) in prescribed drugs, dispensed to pediatric outpatients in Sweden. METHODS: A cross sectional study was conducted based on data from a national register of prescribed drugs, dispensed at pharmacies, to children 0–17 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Holm, Johan, Eiermann, Birgit, Kimland, Elin, Mannheimer, Buster
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681954/
https://www.ncbi.nlm.nih.gov/pubmed/31381591
http://dx.doi.org/10.1371/journal.pone.0220685
_version_ 1783441797137039360
author Holm, Johan
Eiermann, Birgit
Kimland, Elin
Mannheimer, Buster
author_facet Holm, Johan
Eiermann, Birgit
Kimland, Elin
Mannheimer, Buster
author_sort Holm, Johan
collection PubMed
description PURPOSE: To describe the occurrence of potential drug-drug interactions (DDIs) in prescribed drugs, dispensed to pediatric outpatients in Sweden. METHODS: A cross sectional study was conducted based on data from a national register of prescribed drugs, dispensed at pharmacies, to children 0–17 years old. The study period was January 1 to April 30, 2010. Drug dispensing data was linked to the DDI database SFINX. Prevalence and frequencies of potential interactions were investigated, and drugs commonly involved in interactions were identified. The study focused on clinically relevant potential interactions, class D (should be avoided), and class C (can be handled, e.g. by dose adjustment). RESULTS: In the Swedish pediatric population, 0 to 17 years of age, 12% (n = 231 078) of children had at least two dispensed drugs. In this group of patients, 0.14% had potential D-interactions and 1,3% had potential C-interactions. The number of D- and C-interactions that may lead to reduced effects were 181 (52%), and 1224 (32%) respectively. The ten most frequent drugs were involved in 78% and 65% of all potential D-, and C-interactions respectively. Furthermore, 80%, and 58% of the D-, and C-interactions respectively occurred in patients aged 12 to 17. CONCLUSIONS: We identified a limited number of drugs that were represented in the majority of potential interactions. Interactions that can lead to a reduced treatment effect constituted approximately half of D-interactions, and a third of C-interactions. The frequency of potential interactions was higher in older children. The results may contribute to increased prescriber awareness of important potential drug interactions among pediatric outpatients.
format Online
Article
Text
id pubmed-6681954
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-66819542019-08-15 Prevalence of potential drug-drug interactions in Swedish pediatric outpatients Holm, Johan Eiermann, Birgit Kimland, Elin Mannheimer, Buster PLoS One Research Article PURPOSE: To describe the occurrence of potential drug-drug interactions (DDIs) in prescribed drugs, dispensed to pediatric outpatients in Sweden. METHODS: A cross sectional study was conducted based on data from a national register of prescribed drugs, dispensed at pharmacies, to children 0–17 years old. The study period was January 1 to April 30, 2010. Drug dispensing data was linked to the DDI database SFINX. Prevalence and frequencies of potential interactions were investigated, and drugs commonly involved in interactions were identified. The study focused on clinically relevant potential interactions, class D (should be avoided), and class C (can be handled, e.g. by dose adjustment). RESULTS: In the Swedish pediatric population, 0 to 17 years of age, 12% (n = 231 078) of children had at least two dispensed drugs. In this group of patients, 0.14% had potential D-interactions and 1,3% had potential C-interactions. The number of D- and C-interactions that may lead to reduced effects were 181 (52%), and 1224 (32%) respectively. The ten most frequent drugs were involved in 78% and 65% of all potential D-, and C-interactions respectively. Furthermore, 80%, and 58% of the D-, and C-interactions respectively occurred in patients aged 12 to 17. CONCLUSIONS: We identified a limited number of drugs that were represented in the majority of potential interactions. Interactions that can lead to a reduced treatment effect constituted approximately half of D-interactions, and a third of C-interactions. The frequency of potential interactions was higher in older children. The results may contribute to increased prescriber awareness of important potential drug interactions among pediatric outpatients. Public Library of Science 2019-08-05 /pmc/articles/PMC6681954/ /pubmed/31381591 http://dx.doi.org/10.1371/journal.pone.0220685 Text en © 2019 Holm et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Holm, Johan
Eiermann, Birgit
Kimland, Elin
Mannheimer, Buster
Prevalence of potential drug-drug interactions in Swedish pediatric outpatients
title Prevalence of potential drug-drug interactions in Swedish pediatric outpatients
title_full Prevalence of potential drug-drug interactions in Swedish pediatric outpatients
title_fullStr Prevalence of potential drug-drug interactions in Swedish pediatric outpatients
title_full_unstemmed Prevalence of potential drug-drug interactions in Swedish pediatric outpatients
title_short Prevalence of potential drug-drug interactions in Swedish pediatric outpatients
title_sort prevalence of potential drug-drug interactions in swedish pediatric outpatients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681954/
https://www.ncbi.nlm.nih.gov/pubmed/31381591
http://dx.doi.org/10.1371/journal.pone.0220685
work_keys_str_mv AT holmjohan prevalenceofpotentialdrugdruginteractionsinswedishpediatricoutpatients
AT eiermannbirgit prevalenceofpotentialdrugdruginteractionsinswedishpediatricoutpatients
AT kimlandelin prevalenceofpotentialdrugdruginteractionsinswedishpediatricoutpatients
AT mannheimerbuster prevalenceofpotentialdrugdruginteractionsinswedishpediatricoutpatients